Evidence map›Paper›PMID 38178212›Full record

ArticleRespiratory research2024

Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.

Katharina Buschulte, Hans-Joachim Kabitz, Lars Hagmeyer, Peter Hammerl, Albert Esselmann, Conrad Wiederhold, Dirk Skowasch, Christoph Stolpe, Marcus Joest, Stefan Veitshans and 14 more

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 1 country.

Katharina BuschulteCenter for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany. katharina.buschulte@med.uni-heidelberg.de.
Hans-Joachim KabitzMedical Clinic II, Pneumology and Intensive Care Medicine, Klinikum Konstanz, Konstanz, Germany.
Lars HagmeyerHospital Bethanien Solingen, Clinic of Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Solingen, Germany.
Peter HammerlChest Clinic Immenhausen, Immenhausen, Germany.
Albert EsselmannOutpatient Center for Pulmonology, Warendorf, Germany.
Conrad WiederholdOutpatient Center for Pulmonology, Fulda, Germany.
Dirk SkowaschDepartment of Medicine II, University Hospital Bonn, Bonn, Germany.
Christoph StolpeOutpatient Center for Pulmonology, Ibbenbüren, Germany.
Marcus JoestOutpatient Center for Pulmonology and Allergology, Bonn, Germany.
Stefan VeitshansOutpatient Center for Pulmonology, Böblingen, Germany.
Marc HöffgenOutpatient Center for Pulmonology, Rheine, Germany.
Phillen MaqhuzuInstitute of Health Economics and Healthcare Management, Helmholtz Centre Munich GmbH, German Research Centre for Environmental Health, German Centre for Lung Research (DZL), Comprehensive Pneumology Centre Munich (CPCM), Neuherberg, Germany.
Larissa SchwarzkopfInstitute of Health Economics and Healthcare Management, Helmholtz Centre Munich GmbH, German Research Centre for Environmental Health, German Centre for Lung Research (DZL), Comprehensive Pneumology Centre Munich (CPCM), Neuherberg, Germany.
Andreas HellmannOutpatient Center for Pulmonology, Augsburg, Germany.
Michael PfeiferMedical Clinic II, University of Regensburg and Klinikum Donaustauf, Donaustauf, Germany.
Jürgen BehrDepartment of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Centre, German Center for Lung Research (DZL), Munich, Germany.
Rainer KarpaviciusPatient Support Group Lungenfibrose e.V., Essen, Germany.
Andreas GüntherMedical Clinic II, University Hospital Giessen, Universities of Giessen and Marburg Lung Centre (UGMLC), German Center for Lung Research (DZL), Giessen, Germany.
Markus PolkeCenter for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
Philipp HögerCenter for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
Vivien SomogyiMainz Center for Pulmonary Medicine, Departments of Pneumology, ZfT, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
Christoph LedererCenter for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
Philipp MarkartMedical Clinic II, University Hospital Giessen, Universities of Giessen and Marburg Lung Centre (UGMLC), German Center for Lung Research (DZL), Giessen, Germany.
Michael KreuterMainz Center for Pulmonary Medicine, Departments of Pneumology, ZfT, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany. Michael.Kreuter@marienhaus.de.
German Center for Lung Research · DEHelmholtz Zentrum München · DEHeidelberg University · DEJohannes Gutenberg University Mainz · DEKlinik Donaustauf · DEKlinikum Fulda · DEKlinikum Konstanz · DEKlinikum Rheine · DEKrankenhaus Bethanien · DELudwig-Maximilians-Universität München · DEUniversities of Giessen and Marburg Lung Center · DEUniversity Hospital Bonn · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD.

methodsThe EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection.

resultsIn total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005).

conclusionOur results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted.

Indexed as

Connective Tissue DiseasesIdiopathic Pulmonary FibrosisLung Diseases, InterstitialDisease ProgressionHospitalizationHumansRegistriesHospitalisationILDIPFPrognosisRisk factors

Identifiers

PMID38178212
PMCPMC10765927
OpenAlexW4390585496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.